Overview

Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung CancerA Prospective, Single-Arm, Phase II Study

Status:
RECRUITING
Trial end date:
2028-12-10
Target enrollment:
Participant gender:
Summary
In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Zibo Municipal Hospital